Sunliang Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sunliang Cui has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
Linwei Zeng
Institute of Drug Discovery and Design, College of Pharmaceutical Sciences
27 shared publicationsJiaming Li
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
16 shared publicationsZhencheng Lai
Institute of Drug Discovery and Design, College of Pharmaceutical Sciences
16 shared publicationsBo Huang
Department of Chemistry, University of South Florida, 4202 E. Fowler Avenue, Tampa, Florida 33620, United States
12 shared publicationsYangyong Shen
Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
12 shared publicationsJifeng Qi
College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, PR China
10 shared publications
Latest Publications
- 12 August 2026
- Published by Wiley in British Journal of Pharmacology
Therapeutic potential of tanshinones in ischaemia–reperfusion injury: Bioactive analogues, pharmacology and mechanisms
Ischaemia–reperfusion (I/R) injury affects vital organs, including the heart, brain, liver and kidney, and represents a major pathological process associated with high morbidity and mortality. I/R injury initiates complex molecular and cellular cascades that drive cellular dysfunction, structural damage and both acute and chronic organ failure. Despite advances in supportive care, pharmacological intervention remains the primary strategy for protecting organs from I/R injury. Tanshinones, a group of lipophilic abietane diterpenoids derived from Salvia miltiorrhiza , display convergent, multi‐target pharmacological activities that closely correspond to the core pathogenic mechanisms of I/R injury. Over the past two decades, tanshinones, particularly Tan IIA, Tan I and cryptotanshinone, have shown cardioprotective and neuroprotective effects. Increasing evidence further indicates that tanshinones also protect against I/R injury in other organs. This review synthesizes current findings on bioactive tanshinone analogues, their pharmacodynamic properties and underlying mechanisms of action and discusses biomarker‐guided strategies to advance tanshinones as practical, pleiotropic therapeutic candidates for multi‐organ I/R injury.
- 12 August 2026
- Published by Wiley in British Journal of Pharmacology
Therapeutic potential of tanshinones in ischaemia–reperfusion injury: Bioactive analogues, pharmacology and mechanisms
Ischaemia–reperfusion (I/R) injury affects vital organs, including the heart, brain, liver and kidney, and represents a major pathological process associated with high morbidity and mortality. I/R injury initiates complex molecular and cellular cascades that drive cellular dysfunction, structural damage and both acute and chronic organ failure. Despite advances in supportive care, pharmacological intervention remains the primary strategy for protecting organs from I/R injury. Tanshinones, a group of lipophilic abietane diterpenoids derived from Salvia miltiorrhiza , display convergent, multi‐target pharmacological activities that closely correspond to the core pathogenic mechanisms of I/R injury. Over the past two decades, tanshinones, particularly Tan IIA, Tan I and cryptotanshinone, have shown cardioprotective and neuroprotective effects. Increasing evidence further indicates that tanshinones also protect against I/R injury in other organs. This review synthesizes current findings on bioactive tanshinone analogues, their pharmacodynamic properties and underlying mechanisms of action and discusses biomarker‐guided strategies to advance tanshinones as practical, pleiotropic therapeutic candidates for multi‐organ I/R injury.
- Open Access
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Bridged scaffold editing of carbocycles and heterocycles
Bridged frameworks are widely recognized as privileged motifs in natural products and pharmaceuticals, and their distinctive three-dimensional architectures often underpin target recognition and bioactivity. However, their preparation remains a formidable challenge, with most strategies relying on either linear multi-step syntheses or structurally specialized substrates. Here we report a bridged scaffold editing strategy for heterocycles and carbocycles, which employs formaldehyde and ureas in a distinct multicomponent reaction, toward modular and efficient construction of diverse bridged polycycles. Notably, this protocol enables concurrent C(sp²)-H and unactivated C(sp³)-H functionalization, for directly assembling bridged polycyclic products from planar or quasi-planar cyclic substrates through regio- and diastereoselective multiple bond formations. Experimental and computational studies collectively elucidate the plausible reaction pathways underlying these transformations. By offering rapid and general access to three-dimensional polycyclic skeletons, this approach expands the molecular editing toolbox and provides a versatile platform for generating structurally unique compounds with potential applications in drug discovery.
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBridged scaffold editing of carbocycles and heterocycles
Bridged frameworks are widely recognized as privileged motifs in natural products and pharmaceuticals, and their distinctive three-dimensional architectures often underpin target recognition and bioactivity. However, their preparation remains a formidable challenge, with most strategies relying on either linear multi-step syntheses or structurally specialized substrates. Here we report a bridged scaffold editing strategy for heterocycles and carbocycles, which employs formaldehyde and ureas in a distinct multicomponent reaction, toward modular and efficient construction of diverse bridged polycycles. Notably, this protocol enables concurrent C(sp²)-H and unactivated C(sp³)-H functionalization, for directly assembling bridged polycyclic products from planar or quasi-planar cyclic substrates through regio- and diastereoselective multiple bond formations. Experimental and computational studies collectively elucidate the plausible reaction pathways underlying these transformations. By offering rapid and general access to three-dimensional polycyclic skeletons, this approach expands the molecular editing toolbox and provides a versatile platform for generating structurally unique compounds with potential applications in drug discovery.
- 11 February 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (7) , 7804-7815
Chemical Evolution of Natural Product for Discovery and Mechanistic Exploration of Antibiotic against MRSA
Methicillin-resistant Staphylococcus aureus (MRSA) is the most threatening infectious resistant bacterium worldwide, thus the discovery of effective antibiotics against MRSA is a critical global priority. In this study, we report the chemical evolution of a natural product to discover a novel and potent antibiotic candidate. Specifically, neocryptotanshinone was semisynthetically modified, and its enantiomeric derivative (S)-7n demonstrated pronounced efficacy in vitro and in vivo for treating MRSA infection. This candidate was effective against vancomycin-resistant S. aureus (VRSA) and various clinical MRSA isolates, while exhibiting low toxicity. Mechanistic exploration suggests that (S)-7n exerts a dual antibacterial action, combining selective membrane depolarization with perturbation of the transcriptional regulator TetR/AcrR, likely independent of classical efflux pump control. This dual mechanism facilitates potent biofilm eradication, bacteria growth inhibition, and synergistic activity with specific antibiotics. Collectively, this work establishes (S)-7n as a promising, mechanistically novel lead compound and provides a natural product-inspired strategy to overcome MRSA resistance.
- 11 February 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (7) , 7804-7815
Chemical Evolution of Natural Product for Discovery and Mechanistic Exploration of Antibiotic against MRSA
Methicillin-resistant Staphylococcus aureus (MRSA) is the most threatening infectious resistant bacterium worldwide, thus the discovery of effective antibiotics against MRSA is a critical global priority. In this study, we report the chemical evolution of a natural product to discover a novel and potent antibiotic candidate. Specifically, neocryptotanshinone was semisynthetically modified, and its enantiomeric derivative (S)-7n demonstrated pronounced efficacy in vitro and in vivo for treating MRSA infection. This candidate was effective against vancomycin-resistant S. aureus (VRSA) and various clinical MRSA isolates, while exhibiting low toxicity. Mechanistic exploration suggests that (S)-7n exerts a dual antibacterial action, combining selective membrane depolarization with perturbation of the transcriptional regulator TetR/AcrR, likely independent of classical efflux pump control. This dual mechanism facilitates potent biofilm eradication, bacteria growth inhibition, and synergistic activity with specific antibiotics. Collectively, this work establishes (S)-7n as a promising, mechanistically novel lead compound and provides a natural product-inspired strategy to overcome MRSA resistance.
- 5 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1507-1529
Discovery of Novel Nonsteroidal SGRMs of Sulfonamide-2-Oxo-Tetrahydroquinoline Derivatives by Carbonyl Migration
Glucocorticoids (GCs) are limited by severe side effects, driving the development of selective glucocorticoid receptor modulators (SGRMs) with improved therapeutic profiles. We previously development the SGRM lead B53, which suffered from poor metabolic stability. In this study, structure-guided optimization of B53 yielded 43 novel sulfonamide derivatives. Among them, D8, which contained 2-oxo-tetrahydroquinoline by carbonyl migration form B53, manifests an excellent SGRM with remarkable transrepression potency (IC50NF-κB = 0.9 nM) superior to dexamethasone (IC50 NF-κB = 5.0 nM). Besides, D8 exhibits a significantly higher specificity for GR over AR, MR, and PR and exhibited less adverse effects on osteoprotegerin. Furthermore, D8 demonstrated improved metabolic stability and optimized binding mode within the GR LBD. In vivo, oral administration of D8 significantly alleviated dermatitis and autoimmune hepatitis in mouse models, underscoring its therapeutic potential and validating our design strategy.
- 5 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1507-1529
Discovery of Novel Nonsteroidal SGRMs of Sulfonamide-2-Oxo-Tetrahydroquinoline Derivatives by Carbonyl Migration
Glucocorticoids (GCs) are limited by severe side effects, driving the development of selective glucocorticoid receptor modulators (SGRMs) with improved therapeutic profiles. We previously development the SGRM lead B53, which suffered from poor metabolic stability. In this study, structure-guided optimization of B53 yielded 43 novel sulfonamide derivatives. Among them, D8, which contained 2-oxo-tetrahydroquinoline by carbonyl migration form B53, manifests an excellent SGRM with remarkable transrepression potency (IC50NF-κB = 0.9 nM) superior to dexamethasone (IC50 NF-κB = 5.0 nM). Besides, D8 exhibits a significantly higher specificity for GR over AR, MR, and PR and exhibited less adverse effects on osteoprotegerin. Furthermore, D8 demonstrated improved metabolic stability and optimized binding mode within the GR LBD. In vivo, oral administration of D8 significantly alleviated dermatitis and autoimmune hepatitis in mouse models, underscoring its therapeutic potential and validating our design strategy.
- 4 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Discovery of γ-Tetrahydrocarboline Derivatives as Plasmodium falciparum Histone Deacetylase Inhibitors for Treatment of Malaria
Malaria is a life-threatening infectious disease caused by Plasmodium parasites, and the emergence of widespread resistance to existing therapies underscores the urgent need for novel antimalarial agents. Quisinostat was identified as a Plasmodium falciparum histone deacetylase 1 (PfHDAC1) inhibitor against drug-resistant malaria parasites but suffered from intolerable toxicity. To achieve a potent and safe antimalarial agent, we hypothesized a scaffold hopping and linker optimization strategy, in which a total of 33 new structural γ-tetrahydrocarboline derivatives were synthesized and subjected to comprehensive evaluation. Compound 5ac was identified as a PfHDAC1 inhibitor with favorable safety profiles (Pf3D7 IC50 = 4.1 nM, HepG2 IC50 = 1.5 μM, SI = 358; HEK293T IC50 = 15 μM, SI = 3573), improved physicochemical properties, and potent in vivo antimalarial activity. Mechanistic studies showed that 5ac could downregulate the expression of malaria invasion-related genes. Overall, this study establishes γ-tetrahydrocarboline derivatives as new structurally promising PfHDAC-targeted antimalarial agents.
- 4 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Discovery of γ-Tetrahydrocarboline Derivatives as Plasmodium falciparum Histone Deacetylase Inhibitors for Treatment of Malaria
Malaria is a life-threatening infectious disease caused by Plasmodium parasites, and the emergence of widespread resistance to existing therapies underscores the urgent need for novel antimalarial agents. Quisinostat was identified as a Plasmodium falciparum histone deacetylase 1 (PfHDAC1) inhibitor against drug-resistant malaria parasites but suffered from intolerable toxicity. To achieve a potent and safe antimalarial agent, we hypothesized a scaffold hopping and linker optimization strategy, in which a total of 33 new structural γ-tetrahydrocarboline derivatives were synthesized and subjected to comprehensive evaluation. Compound 5ac was identified as a PfHDAC1 inhibitor with favorable safety profiles (Pf3D7 IC50 = 4.1 nM, HepG2 IC50 = 1.5 μM, SI = 358; HEK293T IC50 = 15 μM, SI = 3573), improved physicochemical properties, and potent in vivo antimalarial activity. Mechanistic studies showed that 5ac could downregulate the expression of malaria invasion-related genes. Overall, this study establishes γ-tetrahydrocarboline derivatives as new structurally promising PfHDAC-targeted antimalarial agents.
- 28 August 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- p. 15844-15856
Development and Mechanistic Exploration of Rhodium-Catalyzed Biaxially Atroposelective Click Chemistry
- 28 August 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- p. 15844-15856
Development and Mechanistic Exploration of Rhodium-Catalyzed Biaxially Atroposelective Click Chemistry
- 1 July 2025
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 58 (14) , 2317-2331
Novel Mannich-Type Multicomponent Reactions: Discovery, Mechanism, and Application
ConspectusThe development of efficient multicomponent reactions (MCRs) represents a vital frontier for the rapid construction of structurally sophisticated molecules from simple precursors in an atom- and step-economic manner. In particular, the Mannich reaction is a prototypical three-component reaction that rapidly assembles a resonance-stabilized carbon nucleophile, an aldehyde (or ketone), and an amine to afford alkylamines and serves as a particularly valuable tool for diversity-oriented synthesis in drug discovery and development. Typically, the nucleophilic components of the Mannich reaction rely on Brønsted-acidic carbonyl C(sp3)-H and electron-rich aromatic C(sp2)-H. However, the development of Mannich reactions involving unactivated C(sp3)-H remains a formidable challenge, which would be largely attributed to their difficult deprotonation and therefore non-nucleophilic properties.In this Account, we detail the journey from a serendipitous discovery to mechanistic elucidation, wherein an unprecedented double Mannich alkylamination occurred in both C(sp2)-H and unactivated benzylic C(sp3)-H bonds to eventually enable alkylaminative cyclization. Mechanistic studies revealed a distinctive pathway in which a multiple Mannich and retro-Mannich process and the dehydrogenation of benzylic C(sp3)-H bonds were key steps to constitute the alkylamination. Enlightened by the mechanistic investigations, our group successfully developed a series of Mannich-type MCRs in which benzofurans/indoles, formaldehyde, and alkylamine hydrochlorides assemble efficiently to furnish piperidine-fused benzofurans/indoles, demonstrating broad compatibility with medicinally relevant functionalities. Inspired by the dual C(sp2)-H/C(sp3)-H alkylaminative cyclization paradigm, we developed a unique Mannich-type MCR of indoles wherein the MCR process occurred in both N-H and the adjacent 2-position C(sp2)-H bonds to access indole-fused seven-membered heterocycles.More importantly, these MCRs serve as a powerful synthetic toolbox in the scaffold evolution of natural products as well as in drug discovery and development. Notably, the modification of natural products (NPs) presents significant challenges due to their inherent structural complexity, and thus efficient synthetic methods could enable more accessible modification of NPs, thereby unlocking their full therapeutic potential. We employed our established MCRs to successfully achieve an innovative scaffold evolution of natural product tanshinones, in which the highly lipophilic tanshinones could be easily transformed to N-heterocyclic scaffolds with improved functionality, drug-likeness, and biological specificity. As a result, we have pioneered the chemical evolution of Tan I for the discovery of a new class of potent NLRP3 inflammasome inhibitors and the chemical evolution of Tan IIA for the effective treatment of ALI. Furthermore, leveraging these MCRs to access a privileged scaffold, we have successfully developed a number of promising candidates, including the novel HDAC inhibitors, intestine specific P-gp inhibitors, and STAT3 inhibitors, each showing significant potential for further advancement. Finally, it is anticipated that these MCRs will become essential tools in modern medicinal chemistry and expedite the discovery of new therapeutic agents.
- 1 July 2025
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 58 (14) , 2317-2331
Novel Mannich-Type Multicomponent Reactions: Discovery, Mechanism, and Application
ConspectusThe development of efficient multicomponent reactions (MCRs) represents a vital frontier for the rapid construction of structurally sophisticated molecules from simple precursors in an atom- and step-economic manner. In particular, the Mannich reaction is a prototypical three-component reaction that rapidly assembles a resonance-stabilized carbon nucleophile, an aldehyde (or ketone), and an amine to afford alkylamines and serves as a particularly valuable tool for diversity-oriented synthesis in drug discovery and development. Typically, the nucleophilic components of the Mannich reaction rely on Brønsted-acidic carbonyl C(sp3)-H and electron-rich aromatic C(sp2)-H. However, the development of Mannich reactions involving unactivated C(sp3)-H remains a formidable challenge, which would be largely attributed to their difficult deprotonation and therefore non-nucleophilic properties.In this Account, we detail the journey from a serendipitous discovery to mechanistic elucidation, wherein an unprecedented double Mannich alkylamination occurred in both C(sp2)-H and unactivated benzylic C(sp3)-H bonds to eventually enable alkylaminative cyclization. Mechanistic studies revealed a distinctive pathway in which a multiple Mannich and retro-Mannich process and the dehydrogenation of benzylic C(sp3)-H bonds were key steps to constitute the alkylamination. Enlightened by the mechanistic investigations, our group successfully developed a series of Mannich-type MCRs in which benzofurans/indoles, formaldehyde, and alkylamine hydrochlorides assemble efficiently to furnish piperidine-fused benzofurans/indoles, demonstrating broad compatibility with medicinally relevant functionalities. Inspired by the dual C(sp2)-H/C(sp3)-H alkylaminative cyclization paradigm, we developed a unique Mannich-type MCR of indoles wherein the MCR process occurred in both N-H and the adjacent 2-position C(sp2)-H bonds to access indole-fused seven-membered heterocycles.More importantly, these MCRs serve as a powerful synthetic toolbox in the scaffold evolution of natural products as well as in drug discovery and development. Notably, the modification of natural products (NPs) presents significant challenges due to their inherent structural complexity, and thus efficient synthetic methods could enable more accessible modification of NPs, thereby unlocking their full therapeutic potential. We employed our established MCRs to successfully achieve an innovative scaffold evolution of natural product tanshinones, in which the highly lipophilic tanshinones could be easily transformed to N-heterocyclic scaffolds with improved functionality, drug-likeness, and biological specificity. As a result, we have pioneered the chemical evolution of Tan I for the discovery of a new class of potent NLRP3 inflammasome inhibitors and the chemical evolution of Tan IIA for the effective treatment of ALI. Furthermore, leveraging these MCRs to access a privileged scaffold, we have successfully developed a number of promising candidates, including the novel HDAC inhibitors, intestine specific P-gp inhibitors, and STAT3 inhibitors, each showing significant potential for further advancement. Finally, it is anticipated that these MCRs will become essential tools in modern medicinal chemistry and expedite the discovery of new therapeutic agents.
- 23 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 15798-15811
Discovery of 2-Ethynylisoborneol as a Highly Potent Anti-seizure Agent
Epilepsy is a type of severe neurological disorder that is caused by abnormal neuronal discharges. Natural D-(+)-borneol has been proven to attenuate epileptic seizures, while its potency and pharmacokinetic profiles remain improved. In this study, optimization strategies including prodrug modification, bioisosterism, and metabolic site blocking were performed for aiming to hunt more potent antiseizure borneol derivatives. Thus, various D-(+)-borneol derivatives were prepared and subjected to in vivo antiseizure evaluation with PTZ and MES models. And compound 13 was identified as a promising candidate with favorable pharmacokinetic properties (F = 114.8%) coupled with high and broad-spectrum antiseizure potential. 13 could prolong the latency to stage 6 of the PTZ model from 285.3 to 786.5 s upon oral administration of 30 mg/kg. Mechanistically, 13 was found to ameliorate epileptic seizures via weakening the excitability of glutamatergic transmission. Overall, this work provides a new optimization strategy of borneol and a new chemical entity for epilepsy treatment.
- 23 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 15798-15811
Discovery of 2-Ethynylisoborneol as a Highly Potent Anti-seizure Agent
Epilepsy is a type of severe neurological disorder that is caused by abnormal neuronal discharges. Natural D-(+)-borneol has been proven to attenuate epileptic seizures, while its potency and pharmacokinetic profiles remain improved. In this study, optimization strategies including prodrug modification, bioisosterism, and metabolic site blocking were performed for aiming to hunt more potent antiseizure borneol derivatives. Thus, various D-(+)-borneol derivatives were prepared and subjected to in vivo antiseizure evaluation with PTZ and MES models. And compound 13 was identified as a promising candidate with favorable pharmacokinetic properties (F = 114.8%) coupled with high and broad-spectrum antiseizure potential. 13 could prolong the latency to stage 6 of the PTZ model from 285.3 to 786.5 s upon oral administration of 30 mg/kg. Mechanistically, 13 was found to ameliorate epileptic seizures via weakening the excitability of glutamatergic transmission. Overall, this work provides a new optimization strategy of borneol and a new chemical entity for epilepsy treatment.